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UPITER “Moderate CKD”
ubgroup Is Not Truly “Moderate”
hronic Kidney Disease
iven that trials of lipid lowering in patients with chronic kidney
isease (CKD) requiring dialysis have been neutral (1), and the
nly evidence for lipid-lowering therapy in patients with CKD not
equiring dialysis is based on secondary analyses, such as the
ravastatin Pooling Project (2), it is commendable that a subgroup
efined by kidney function was examined in JUPITER (Justifica-
ion for the Use of Statins in Prevention–an Intervention Trial
valuating Rosuvastatin), as reported recently in this journal (3).
owever, we do not believe that it is appropriate to call this a
ubgroup with “moderate CKD.”
The JUPITER CKD subgroup is influenced by the limitations
f the Modified Diet in Renal Disease (MDRD) equation for
stimating glomerular filtration rate (GFR) and the study inclusion
riteria. Moderate CKD is defined by a GFR of 30 to 59 ml/min,
ith or without other evidence of kidney damage, but should be
resent for 3 months to be truly “chronic” kidney disease (4). The
DRD GFR equation uses the serum creatinine, age, sex, and
frican American ethnicity to estimate GFR but underestimates
FR at higher levels (5). The characteristics of this JUPITER
ubgroup that suggest the term “moderate CKD” is inappropriate
re as follows:
. In the CKD subgroup, 50% of participants had a GFR between
51 and 58 ml/min, and 25% had a GFR between 58 and 60
ml/min (Table 1 [3]). At least one-fourth of patients could have
been misclassified simply due to variability in the creatinine
assay (6). The authors do not report whether creatinine was
measured centrally or what calibration procedures were used.
. Female participants were substantially over-represented in the
CKD subgroup, whereas African-American participants were
substantially under-represented (Table 1 [3]). The multipliers
in the MDRD equation result in lower GFRs for women and
higher GFRs for African Americans with the same serum
creatinine, and the problem of a universal cutoff of 60 ml/min
causing 50% more women than men to be classified as having
CKD has been described (7).
. The 10-year age difference between women and men in the
inclusion criteria may result in more females having a GFR60 ml/min. In an age-specific MDRDGFR “reference range”
in a population free of vascular disease, hypertension, diabetes,
or kidney disease, the median GFR in women age 60 to 64
years was 10 ml/min lower compared with men age 50 to 54
years (7).
The results were described as similar with the Cockroft-Gault
quation, but it would be interesting to see how the characteristics,
r indeed the classification, of the patients was altered.
We do not question the effect of the intervention in the patients
escribed or the use of the MDRD equation for this purpose.
owever, patients seen by nephrologists and cardiologists with a
FR between 30 and 59 ml/min (“moderate” CKD by the
/DOQI [Kidney Disease Outcomes Quality Initiative] classifi-
ation) have a high prevalence of diabetes and cardiovascular
isease (excluded by design in the JUPITER trial) and higher,
ather than lower, systolic blood pressure than people with normal
idney function. We suggest that this JUPITER subgroup is better
escribed as “patients with an MDRD GFR 60 ml/min on
occasion” to avoid inappropriate extrapolation of these results.
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